Beijing-focused pharmaceutical distributor under the Sinopharm state group, also licensed to distribute and produce narcotic/controlled drugs.
Beijing-focused pharmaceutical distributor under the Sinopharm state group, also licensed to distribute and produce narcotic/controlled drugs.
Buys medicines from manufacturers and resells to hospitals and pharmacies at a thin markup, so profit comes from volume; the restricted trade in narcotic and psychotropic drugs, where licensing limits competition, adds a protected line.
In one line: A regional Chinese McKesson/Cardinal Health.
Moat: narrow (regulatory licence, distribution, scale). One of few nationally licensed narcotic-drug distributors, plus Sinopharm's distribution scale.
Headquarters: Beijing, China · Employees: 3,024
Size China National Medicines (600511.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $3.26B, the 744th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥28.79 on 18 Nov 2026.
Performance Over six months the shares gained 3.4%, against -0.7% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue grew 3.4% over the last twelve months (peer median +25.5%); the operating margin is 3.8% (peer median 12.0%).
Valuation It trades at 10.5× forward earnings against a peer median of 22.1× (cheapest of 15).
Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -15 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.5 points above its cost of capital (5.0% WACC).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥53.7B | CN¥52.4B | CN¥50.5B | CN¥49.6B | CN¥45.4B |
| Revenue growth | — | +4% | +2% | +9% | — |
| Gross profit | CN¥3.59B | CN¥3.20B | CN¥3.35B | CN¥3.77B | CN¥3.60B |
| EBITDA | n/a | CN¥2.27B | CN¥2.35B | CN¥2.58B | CN¥2.42B |
| Net income | CN¥1.98B | CN¥2.00B | CN¥2.00B | CN¥2.15B | CN¥1.96B |
| Free cash flow | CN¥1.63B | CN¥1.97B | CN¥1.55B | CN¥2.59B | CN¥2.27B |
| Capital expenditure | CN¥69.3M | CN¥68.2M | CN¥131M | CN¥145M | CN¥130M |
| Total debt | CN¥2.93B | CN¥4.58B | CN¥4.35B | CN¥3.16B | CN¥3.06B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| China National Medicines 600511.SS | $3.26B | +3% | +3% | 4% | 10.5× | -10.0% |
| Sinopharm 1099.HK | $6.74B | 0% | +3% | 3% | 6.2× | -7.3% |
| China Resources Pharmaceutical 3320.HK | $3.60B | -7% | +8% | 4% | 5.8× | -4.9% |
| Shanghai Pharmaceuticals 601607.SS | $8.23B | 0% | +4% | 3% | 11.2× | -10.1% |
| Jointown Pharmaceutical 600998.SS | $3.99B | +7% | +9% | 2% | 11.8× | 0.2% |
| Nanjing Pharmaceutical 600713.SS | $999M | -2% | +3% | 2% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600511.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.0% | -3.4% | 6th highest of 21 |
| 6-month return | +3.4% | -0.7% | 10th highest of 20 |
| Distance from 52-week high | -7.7% | -29.6% | 4th highest of 21 |
| Revenue growth (TTM) | +3.4% | +25.5% | 6th lowest of 19 |
| Operating margin | 3.8% | 12.0% | 5th lowest of 18 |
| Forward P/E | 10.5× | 22.1× | cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -10.0% | 9.2% | least demanding of 12 |
| Growth delivered (Del g) | +5.4% | +12.0% | 4th lowest of 12 |
| Hurdle (Req g minus delivered) | -15.4 pp | -10.2 pp | 4th least demanding of 12 |
| ROIC minus cost of capital | +4.5 pp | +6.6 pp | 9th highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| China National Medicines 600511.SS | China | $3.26B | +3% | +3% | 4% | 10.5× | -10.0% | +5.4% |
| Tasly Pharmaceutical 600535.SS | China | $3.19B | -2% | -4% | 19% | 16.7× | -7.5% | -9.6% |
| Viking Therapeutics VKTX | United States | $3.34B | -9% | n/a | n/a | n/a | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.37B | +17% | -16% | 10% | 22.9× | 4.7% | +4.5% |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.13B | -25% | +136% | 29% | 36.1× | 17.7% | +98.4% |
| Legend Biotech Corp. Sponsored ADR LEGN | United States | $3.12B | -42% | +50% | 3% | 34.2× | n/a | n/a |
| Piramal Pharma PPLPHARMA.NS | India | $3.40B | +38% | +9% | 3% | 150.8× | n/a | n/a |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.42B | -5% | +27% | 18% | 13.5× | -3.4% | +10.6% |
| Viridian Therapeutics VRDN | United States | $3.42B | +71% | -63% | -1,781% | n/a | n/a | n/a |
| Amylyx Pharmaceuticals AMLX | United States | $3.42B | +93% | +100% | n/a | n/a | n/a | n/a |
| ACADIA Pharmaceuticals ACAD | United States | $3.08B | -15% | +15% | 10% | 17.8× | 9.2% | +19.4% |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.05B | -39% | +33% | 12% | 21.3× | 14.1% | +61.4% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 19.6× | -2.1% | +12.0% |
| Shanghai Junshi Biosciences 688180.SS | China | $3.48B | -31% | +29% | -15% | n/a | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 41.0× | 49.2% | +367.3% |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 63.6× | n/a | n/a |
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 16.8× | n/a | n/a |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | n/a | 58.0% | +4.2% |
| Vericel VCEL | United States | $2.99B | +66% | +25% | 8% | 68.3× | 46.5% | +17.3% |
| Chengdu Kanghong Pharmaceutical 002773.SZ | China | $2.99B | -1% | -11% | 24% | 20.1× | -3.3% | +7.0% |